GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biohaven Ltd (NYSE:BHVN) » Definitions » ROA %

BHVN (Biohaven) ROA % : -117.31% (As of Sep. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Biohaven ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Biohaven's annualized Net Income for the quarter that ended in Sep. 2024 was $-641.22 Mil. Biohaven's average Total Assets over the quarter that ended in Sep. 2024 was $546.58 Mil. Therefore, Biohaven's annualized ROA % for the quarter that ended in Sep. 2024 was -117.31%.

The historical rank and industry rank for Biohaven's ROA % or its related term are showing as below:

BHVN' s ROA % Range Over the Past 10 Years
Min: -168.64   Med: -124.16   Max: -69.48
Current: -167.04

During the past 4 years, Biohaven's highest ROA % was -69.48%. The lowest was -168.64%. And the median was -124.16%.

BHVN's ROA % is ranked worse than
91.15% of 1503 companies
in the Biotechnology industry
Industry Median: -35.81 vs BHVN: -167.04

Biohaven ROA % Historical Data

The historical data trend for Biohaven's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biohaven ROA % Chart

Biohaven Annual Data
Trend Dec20 Dec21 Dec22 Dec23
ROA %
-106.43 -168.64 -141.89 -69.48

Biohaven Quarterly Data
Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -92.26 -129.25 -154.12 -255.52 -117.31

Competitive Comparison of Biohaven's ROA %

For the Biotechnology subindustry, Biohaven's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biohaven's ROA % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biohaven's ROA % distribution charts can be found below:

* The bar in red indicates where Biohaven's ROA % falls into.



Biohaven ROA % Calculation

Biohaven's annualized ROA % for the fiscal year that ended in Dec. 2023 is calculated as:

ROA %=Net Income (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=-408.168/( (661.783+513.212)/ 2 )
=-408.168/587.4975
=-69.48 %

Biohaven's annualized ROA % for the quarter that ended in Sep. 2024 is calculated as:

ROA %=Net Income (Q: Sep. 2024 )/( (Total Assets (Q: Jun. 2024 )+Total Assets (Q: Sep. 2024 ))/ count )
=-641.216/( (582.641+510.523)/ 2 )
=-641.216/546.582
=-117.31 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Sep. 2024) net income data. ROA % is displayed in the 30-year financial page.


Biohaven  (NYSE:BHVN) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Sep. 2024 )
=Net Income/Total Assets
=-641.216/546.582
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-641.216 / 0)*(0 / 546.582)
=Net Margin %*Asset Turnover
=N/A %*0
=-117.31 %

Note: The Net Income data used here is four times the quarterly (Sep. 2024) net income data. The Revenue data used here is four times the quarterly (Sep. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Biohaven ROA % Related Terms

Thank you for viewing the detailed overview of Biohaven's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Biohaven Business Description

Traded in Other Exchanges
N/A
Address
215 Church Street, New Haven, CT, USA, 06510
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. Its products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.
Executives
John W Childs director 111 HUNTINGTON AVENUE, SUITE 2900, BOSTON MA 02199
Vlad Coric director, officer: Chief Executive Officer C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510
Gregory Bailey director 4 A CHESHAM STREET, LONDON X0 SW1X8DT
Bruce Car officer: Chief Scientific Officer AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139
Irina Antonijevic director 215 CHURCH STREET, NEW HAVEN CT 06510
Matthew Buten officer: Chief Financial Officer 215 CHURCH STREET, NEW HAVEN CT 06510
George C. Clark officer: VP, Chief Accounting Officer 215 CHURCH STREET, NEW HAVEN CT 06510
Julia P Gregory director 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381
Robert J Hugin director C/O THE MEDICINES CO, 8 CAMPUS DR, PARSIPPANY NJ 07054
Michael Thomas Heffernan director C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Kimberly Gentile officer: SVP, Clinical Operations C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510
Kishan Mehta director 540 WEST 49TH STREET, UNIT# PH1N, NEW YORK NY 10019
Biohaven Pharmaceutical Holding Co Ltd. 10 percent owner 215 CHURCH STREET, NEW HAVEN CT 06510